Tolvaptan (Samsca, Otsuka America Pharmaceuticals), indicated for treating clinically significant hypervolemic and euvolemic hyponatremia, poses the risk of causing irreversible and potentially ...

The FDA has issued a drug safety communication concerning tolvaptan (Samsca, Otsuka), a selective vasopression V2-receptor antagonist used in heart failure patients to treat clinically significant ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market. The tablets, bioequivalent to Otsuka's Jynarque, will be manufactured ...

ECLIPSE Casts Light on Mechanisms Behind Tolvaptan's Relief of Heart Failure Symptoms. Steve Stiles. September 21, 2007. September 21, ...